Dosing of first Fabry patient incorporating plato™ anticipated for fourth quarter 2019 All Fabry patients who discontinued enzyme replacement therapy (ERT) following treatment with AVR-RD-01 investigational gene therapy remain off ERT FDA orphan drug designation granted for AVR-RD-02
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2019-- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease.
Company developing commercial strategies and operational capabilities to support future product launches as investigational gene therapies advance through clinic Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct.